Valuation: Gilead Sciences, Inc.

Market Cap 162B 142B 133B 122B 229B 15,540B 232B 1,576B 616B 7,674B 608B 595B 26,523B P/E 2026 *
-47x
P/E 2027 * 16.5x
Enterprise Value 172B 151B 140B 129B 242B 16,461B 245B 1,670B 652B 8,128B 644B 630B 28,093B EV / Sales 2026 *
5.64x
EV / Sales 2027 * 5.02x
Free-Float
99.88%
Yield 2026 *
2.53%
Yield 2027 * 2.61%
1 day+2.83%
1 week+3.35%
Current month+6.58%
1 month+6.59%
3 months+4.17%
6 months-3.63%
Current year+9.70%
1 week 127.61
Extreme 127.61
136.26
1 month 124.19
Extreme 124.19
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 71 2020-10-16
Director/Board Member 73 2017-12-31
Director/Board Member 67 2024-01-31
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+2.91%+3.35%+19.13%+75.19% 162B
+2.12%+4.59%+52.13%+168.14% 1,068B
+2.13%+8.73%+63.94%+56.18% 641B
+3.33%+3.71%+40.89%+76.07% 454B
+2.29%+10.04%+40.94%+36.34% 351B
+1.67%+3.94%+39.79%+44.58% 299B
+0.73%+4.16%+20.59%+17.67% 266B
+2.73%+3.50%-25.66%-36.53% 220B
+4.68%+7.38%+30.53%+66.38% 203B
+2.49%+1.58%+4.22%-29.76% 141B
Average +2.44%+2.28%+28.65%+47.43% 380.39B
Weighted average by Cap. +2.32%+2.67%+39.75%+77.37%

Financials

2026 *2027 *
Net sales 30.42B 26.75B 24.9B 22.87B 42.94B 2,918B 43.5B 296B 116B 1,441B 114B 112B 4,980B 32.3B 28.39B 26.43B 24.27B 45.58B 3,097B 46.18B 314B 123B 1,529B 121B 119B 5,286B
Net income -3.39B -2.98B -2.77B -2.55B -4.78B -325B -4.85B -32.98B -12.88B -161B -12.73B -12.45B -555B 9.78B 8.6B 8B 7.35B 13.8B 938B 13.98B 95.12B 37.15B 463B 36.71B 35.92B 1,601B
Net Debt 9.6B 8.44B 7.85B 7.21B 13.54B 920B 13.72B 93.35B 36.46B 454B 36.03B 35.25B 1,571B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-28 $133.19 +2.05% 2,786,985
26-07-27 $130.52 +0.94% 4,953,801
26-07-24 $129.31 -1.18% 5,529,741
26-07-23 $130.86 +0.40% 6,299,287
26-07-22 $130.34 +0.05% 4,757,764
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.52USD
Average target price
157.52USD
Spread / Average Target
+20.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock